option or options to extend (at the discretion of the Authority) for a period or periods of up to 24 months.
Medicines Procurement and Supply Chain (MPSC) · awarded 24 January 2025 · delivered in England
£36.5m
Award value
£36,522,476
3
Suppliers
Recorded as a large business
31 Jan 2027
Runs until
from 1 Feb 2025
Who
| Buyer | Medicines Procurement and Supply Chain (MPSC) Runcorn |
|---|---|
| Suppliers |
Abbvie Ltd Baxter Healthcare Ltd Piramal Critical care Limited |
| Category | goods |
| Classification | Pharmaceutical products CPV 33600000 |
| Notice published | 31 March 2025 |
What it is for
option or options to extend (at the discretion of the Authority) for a period or periods of up to 24 months. Period of framework agreement: 1st February 2025 to 31st January 2027, with an option or options to extend (at the discretion of the Authority) for a period or periods of up to 24 months.
Read the original award notice on Contracts Finder →
Other contracts from this buyer
2 awards on file, worth £73.0m.
| Awarded | What for | Buyer | Supplier | Value |
|---|---|---|---|---|
| 24 Jan 2025 | NHS National Framework Agreement - Inhalation Anaesthetics and VaporisersEngland | Medicines Procurement and Supply Chain (MPSC) | Abbvie Ltd +2 | £36.5m |
| 24 Jan 2025 | option or options to extend (at the discretion of the Authority) for a period or periods…England | Medicines Procurement and Supply Chain (MPSC) | Abbvie Ltd +2 | £36.5m |
Everything Medicines Procurement and Supply Chain (MPSC) has awarded →
Other contracts won by this supplier
6 awards on file, worth £3.3bn.
| Awarded | What for | Buyer | Supplier | Value |
|---|---|---|---|---|
| 24 Mar 2025 | NHS Framework Agreement for Branded Medicines - Proprietary Category TenderEast Midlands | NHS England | CSL Behring UK Ltd +71 | £1.2bn |
| 1 Jul 2025 | NHS Branded Medicines Tranche B - MAE & NOFE - 1 September 2025 | NHS England | Biogen +20 | £986.3m |
| 28 Oct 2024 | NHS Framework for the supply of Licensed Antiretroviral Therapy (ART) 1 Nov 2024 | NHS England | Gilead Sciences Limited +12 | £626.5m |
| 25 Jul 2024 | NHS National Framework for Medical Retinal Vascular Treatments 1 August 2024 | NHS England | Bayer Plc +8 | £416.8m |
| 24 Jan 2025 | NHS National Framework Agreement - Inhalation Anaesthetics and VaporisersEngland | Medicines Procurement and Supply Chain (MPSC) | Abbvie Ltd +2 | £36.5m |